Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E33.05 EPS (ttm)1.71 Insider Own0.10% Shs Outstand1.67B Perf Week1.58%
Market Cap94.37B Forward P/E18.85 EPS next Y3.00 Insider Trans-21.27% Shs Float1.50B Perf Month-3.60%
Income2.87B PEG1.69 EPS next Q0.64 Inst Own74.30% Short Float0.82% Perf Quarter-19.59%
Sales17.62B P/S5.36 EPS this Y-22.30% Inst Trans-0.07% Short Ratio1.10 Perf Half Y-9.00%
Book/sh8.93 P/B6.32 EPS next Y14.26% ROA9.00% Target Price67.50 Perf Year-6.48%
Cash/sh2.78 P/C20.29 EPS next 5Y19.59% ROE19.60% 52W Range55.02 - 77.12 Perf YTD-16.97%
Dividend1.52 P/FCF- EPS past 5Y-12.20% ROI4.60% 52W High-27.90% Beta0.72
Dividend %2.69% Quick Ratio1.40 Sales past 5Y-3.20% Gross Margin75.70% 52W Low1.05% ATR1.04
Employees25000 Current Ratio1.60 Sales Q/Q17.00% Oper. Margin20.80% RSI (14)32.23 Volatility1.59% 1.88%
OptionableYes Debt/Eq0.45 EPS Q/Q990.60% Profit Margin16.30% Rel Volume0.70 Prev Close56.48
ShortableYes LT Debt/Eq0.44 EarningsOct 27 BMO Payout87.80% Avg Volume11.17M Price55.60
Recom2.50 SMA20-1.55% SMA50-12.06% SMA200-15.93% Volume4,315,716 Change-1.56%
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Oct-27-14Reiterated MKM Partners Sell $34 → $36
Jul-25-14Reiterated MKM Partners Sell $29 → $34
Sep-26-16 11:05AM  How Mylans Profitability Has Changed
Sep-23-16 07:04PM  Generics or Specialty: Which Mylan Segment Is Growing Fastest?
01:04PM  Why Analysts Expect Gileads Revenue to Fall in 2016 and 2017
08:08AM  Gilead Sciences Focuses on a Strong Inorganic Growth Strategy
08:00AM  Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO
Sep-22-16 08:20PM  AVEO Collaborates With Bristol-Myers Squibb for RCC Drug (AVEO, BMY) at Investopedia
02:03PM  Bristol-Myers Squibb Stock Is Down, but That Means You Should Buy
09:38AM  Bristol-Myers Squibb to Take Part in Leerink Partners Immuno-Oncology Roundtable Conference Business Wire
Sep-21-16 10:29AM  Bristol-Myers Opdivo's Regulatory Application Validated in EU
08:04AM  Bristol-Myers Capitalizes on Japanese Markets for Its Cardio Drug
Sep-20-16 11:04AM  Bristol-Myers Squibbs Role in the Multiple Myeloma Market
10:04AM  How Multiple Research Programs in Lung Cancer Space Are Impacting Bristol-Myers Squibb
08:04AM  Multiple Segments of Lung Cancer Create Opportunity for Bristol-Myers Squibbs
06:59AM  European Medicines Agency Validates Bristol-Myers Squibbs Type II Variation Application for Opdivo (nivolumab) in Advanced Form of Bladder Cancer Business Wire
06:59AM  Bristol-Myers Squibb Awards First Golden Tickets for LabCentral to PanTher, Suono Bio Business Wire
Sep-19-16 11:04AM  Bristol-Myers Squibbs Strategic Focus on These Areas Could Boost Overall Growth
10:05AM  What Could Drive Sales from Bristol-Myers Squibbs Cancer Drug even Higher?
08:05AM  What Analysts Think about Bristol-Myers Squibb
08:04AM  Roche Goes Up against Bristol-Myers Squibb in Oncology Drug Space
06:00AM  Trump Means Change Equals Major Inflection Point
Sep-18-16 07:25AM  Trump Means Change Equals a Major Inflection Point
Sep-16-16 06:27PM  What Do 2016 Valuation Multiples Say about Bristol-Myers?
10:15AM  Why this Peninsula biotech's layoffs aren't necessarily a bad thing (except for the 46 people losing their jobs) at bizjournals.com
08:04AM  Roches Oncology Wheelhouse Stacked with Competitive Drugs
Sep-15-16 01:00AM  My Advice For Dealing With An Interest Rate Hike
Sep-14-16 08:02PM  Jim Cramer's 'Mad Money' Recap: Strong Demand Keeps Market From Cratering
06:22PM  Cramer: Bristol-Myers is a screaming value buy at CNBC
06:15PM  Cramer: Bristol-Myers is a screaming value buy
Sep-12-16 10:04AM  Whats the Problem with GSKs Pharmaceutical Segment?
Sep-11-16 07:39AM  3 Great Dividend Stocks in the Bargain Bin for Retirees at Motley Fool
07:36AM  Fed Members Should Talk Less, Guide Better and Think Globally
Sep-08-16 01:09PM  Is Bristol-Myers Squibb Presenting an Opportunity?
11:04AM  Celgene Carves Out More Share of This Cancer Treatment Market
08:30AM  Multi-Billion Dollar Cancer Treatment & Patient Care Industry Boosting Biotech Sector to New Highs CNW Group
08:23AM  This Crushing Blow Sent Bristol-Myers Squibb Co. Down 23% in August at Motley Fool
Sep-07-16 05:45PM  3 Stocks to Help Fund Your Retirement at Motley Fool
11:17AM  Bristol-Myers Squibb to Announce Results for Third Quarter 2016 on October 27 Business Wire
10:59AM  Bristol-Myers' Orencia Gains EU Approval for Expanded Use
10:41AM  Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Global Health Care Conference Business Wire
06:59AM  Bristol-Myers Squibb Employees Cycle Coast to Coast to Raise Money and Awareness for Cancer Research Business Wire
Sep-06-16 06:09PM  New Research Reports for September 6, 2016
12:20PM  Bristol-Myers Squibb (BMY) Stock Gains on EU Drug Approval
12:14PM  Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference Business Wire
06:59AM  European Commission Approves Bristol-Myers Squibbs ORENCIA┬« (abatacept) for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treated with Methotrexate Business Wire
Sep-05-16 10:04AM  How Are Eli Lillys New Products Performing?
08:00AM  VeriFone (PAY), Gilead (GILD) Among 5 Stocks That Hit 52-Week Lows Last Week at Insider Monkey
06:08AM  Stop Fighting the Tape
Sep-03-16 02:00PM  MRK: How Merck's Stock Price Rose 31.42% in 6 Months at Investopedia
Sep-02-16 04:04PM  Bristol-Myers, Verifone Dive into Fridays 52-Week Low Club at 24/7 Wall St.
02:04PM  Is Incyte Hurt by Having Only One FDA-Approved Drug?
01:11PM  Today's Fast Break: CMG, LULU, BMY
12:56PM  Unusual activity: Bristol-Myers
12:30PM  Raymond James: Abbvie has value-enhancing catalysts
01:00AM  This Well-Known Dividend Giant Is On Sale
Sep-01-16 04:35PM  Roche Drug Scores In Lung Cancer, Challenging Bristol-Myers
08:06AM  Is Eli Lillys Valuation Higher than Its Peers?
Aug-31-16 07:05PM  Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ESMO 2016 Congress Highlights Business Wire
12:25PM  Merck: Lung Cancer Lead Depends On "How Smart It Plays Its Hand" at Barrons.com
11:36AM  Why Do Hedge Funds Like Five Prime Therapeutics? at Insider Monkey
11:04AM  Recent Developments at Johnson & Johnson
08:04AM  Franchises that Drove Allergans International Sales in 2Q
Aug-30-16 02:04PM  Analyzing Johnson & Johnsons Business Segments
01:30PM  This Pharma Company Is Leading The Race For A Zika Vaccine
10:00AM  Spotlight (STLT) to Help Fund Breakthrough Drug Research
08:25AM  [$$] Bristol-Myers Squibb misses mark with cancer drug at Financial Times
Aug-29-16 12:26PM  Healthcare's best bets following generic EpiPen
Aug-28-16 07:07AM  Time to Shift Your Focus
Aug-25-16 06:08PM  Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo
Aug-24-16 11:04AM  How Did Bristol-Myers Squibb Fare in 2Q16?
Aug-23-16 06:59AM  Bristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016 Business Wire
Aug-22-16 06:15PM  Allied Minds, Bristol-Myers Squibb to progress first drug to preclinical trials at bizjournals.com
09:06AM  How Did Bristol-Myers Squibbs Oncology Segment Perform in 2Q16?
08:36AM  Bristol-Myers Squibb Stock Will Bounce Back -- Here's How You Can Profit
07:20AM  [$$] Pfizer agrees $14bn takeover of Medivation at Financial Times
12:35AM  [$$] The Profit and Peril of Cancer Drugs at The Wall Street Journal
Aug-21-16 02:11PM  5 Trade Ideas for Monday: Bank of America, Bristol-Myers, DuPont, Halliburton and Mylan
12:33PM  Curbing Excessive Exuberance May be Premature
Aug-20-16 08:07AM  These 3 Stocks Could Boost Their Dividends in the Next 12 Months at Motley Fool
Aug-19-16 05:04PM  How Does Bristol-Myers Squibbs Valuation Compare to Peers?
01:12PM  [$$] The Profit and Peril of Cancer Drugs at The Wall Street Journal
12:41PM  ETFs with exposure to Bristol-Myers Squibb Co. : August 19, 2016
Aug-18-16 04:40PM  Is It "Game Over" After Portola's FDA Rejection? at Motley Fool
Aug-17-16 10:22AM  Bristol-Myers Squibb attracts upside bets
Aug-16-16 10:11AM  Mirror Image: Bristol-Myers Loss Is Merck's Potential Gain
Aug-15-16 03:53PM  Bristol-Myers Squibb (BMY) Stock Falls, Bernstein: Failed Trial Impact to Persist
09:26AM  Bristol-Myers to Reacquire Rights to Oncology Drug in Asia
09:06AM  What Are Mercks Key Diabetes Products?
Aug-14-16 03:02PM  Bristol-Myers' Revolutionary Cancer Drug Suffers A Big Blow at Motley Fool
09:56AM  Stay the Course
07:18AM  3 Beaten-Up Big Pharma Stocks: Are They Bargains? at Motley Fool
Aug-13-16 12:01AM  [$$] 5 Safe European Stocks With Yields Up to 5% at Barrons.com
Aug-12-16 01:42PM  How Risky Is Celldex Therapeutics, Inc.? at Motley Fool
05:50AM  [$$] Samsung biopharma unit lines up South Korea IPO at Financial Times
01:00AM  AstraZeneca Transcends Brexit Woes on Pound Slump, Rivals Flop at Bloomberg
01:00AM  AstraZeneca Rides High, Fueled by Brexit, Bristol-Myers Failure
Aug-11-16 03:53PM  Will Bristol-Myers (BMY) Stock Be Hurt by Downgrade?
08:59AM  The Market In 5 Minutes: Valeant's Fraud, Macy's Beat, And Arianna's Departure
08:16AM  Berenberg Downgrades Bristol-Myers Squibb, Says Competitors Better Exposed For Near-Term Upside
07:38AM  Cramer: Valeant Probe Is a Reminder of the Bristol-Myers Scandal
07:23AM  Bristol-Myers downgraded by Berenberg
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung cancer, renal cell cancer, and melanoma; Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor that is in regulatory review for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ANDREOTTI LAMBERTODirectorSep 08Sale56.9710,800615,276323,699Sep 09 04:41 PM
ANDREOTTI LAMBERTODirectorSep 07Sale56.7710,800613,116334,499Sep 09 04:41 PM
Nielsen AnneChief Compliance & Ethics OffSep 03Option Exercise0.001,596029,722Sep 07 04:33 PM
ANDREOTTI LAMBERTODirectorAug 25Sale58.9211,600683,472345,299Aug 25 05:10 PM
ANDREOTTI LAMBERTODirectorAug 24Sale59.4311,600689,359356,899Aug 25 05:10 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,511015,250Aug 03 04:56 PM
ANDREOTTI LAMBERTODirectorJul 08Sale75.0411,600870,461368,499Jul 11 05:12 PM
ANDREOTTI LAMBERTODirectorJul 07Sale73.8611,600856,776380,099Jul 11 05:12 PM
Blin EmmanuelSVP, Chief Strategy OfficerJul 02Option Exercise0.00951012,516Jul 06 05:58 PM
Gordon MurdoEVP, Chief Commercial OfficerJul 01Option Exercise0.002,335014,950Jul 06 05:58 PM
Cuss Francis MEVP & CSOJul 01Option Exercise0.003,6550291,628Jul 06 05:58 PM
ANDREOTTI LAMBERTODirectorJun 29Sale72.799,800713,342392,194Jun 30 05:42 PM
ANDREOTTI LAMBERTODirectorJun 28Sale71.6713,400960,396390,394Jun 30 05:42 PM
Elicker John ESVP, Public Affairs & IRJun 14Sale72.6911,820859,21955,011Jun 16 04:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMay 20Sale70.7930,2012,137,838184,694May 24 05:04 PM
Caldarella Joseph CSVP & ControllerMay 16Sale72.473,519255,00455,238May 17 04:46 PM
Caforio GiovanniChief Executive OfficerMay 05Option Exercise0.008,0400134,549May 09 04:42 PM
Caforio GiovanniChief Executive OfficerMay 03Option Exercise24.7950,4551,250,602145,958May 05 04:31 PM
Caforio GiovanniChief Executive OfficerMay 03Sale71.3134,5942,466,885117,118May 05 04:31 PM
ANDREOTTI LAMBERTODirectorMay 02Option Exercise26.04234,7206,112,787671,514May 04 05:28 PM
Schmukler Louis SPres., Global Mfg. & SupplyMay 02Sale71.9522,2181,598,65221,971May 04 05:28 PM
ANDREOTTI LAMBERTODirectorMay 02Sale71.88234,72016,870,792436,794May 04 05:28 PM
ANDREOTTI LAMBERTODirectorApr 05Sale66.0011,600765,626436,794Apr 06 04:18 PM
ANDREOTTI LAMBERTODirectorApr 04Sale65.7911,600763,216448,394Apr 06 04:18 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554025,260Apr 05 04:59 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0031,624055,059Mar 14 09:44 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0037,1430300,492Mar 14 09:43 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00204,4470574,101Mar 14 09:43 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,860074,177Mar 14 09:43 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0020,460067,864Mar 14 09:44 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,406089,478Mar 14 09:42 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0060,6230132,906Mar 14 09:42 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0057,4840366,730Mar 14 09:42 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0025,435032,069Mar 14 09:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.008,806059,091Mar 14 09:41 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0075,6180247,158Mar 14 09:41 PM
Blin EmmanuelSVP, Head of CommercializationMar 10Option Exercise0.0011,707013,498Mar 14 09:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 10Option Exercise0.0019,309019,608Mar 14 09:41 PM
CAMPBELL LEWIS BDirectorMar 08Option Exercise24.962,50062,4002,500Mar 10 04:36 PM
CAMPBELL LEWIS BDirectorMar 08Sale66.002,500165,0000Mar 10 04:36 PM
Caforio GiovanniChief Executive OfficerMar 06Option Exercise0.002,889079,627Mar 08 04:42 PM
Gordon MurdoSVP, Head of Worldwide MarketsMar 06Option Exercise0.001,28202,611Mar 08 04:43 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724050,821Mar 08 04:43 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931048,253Mar 08 04:43 PM
LEUNG SANDRAEVP, General CounselMar 06Option Exercise0.005,5740315,121Mar 08 04:41 PM
Elicker John ESVP, Public Affairs & IRMar 06Option Exercise0.001,043053,715Mar 08 04:41 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0100269,043Mar 08 04:42 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,391060,032Mar 08 04:40 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3240169,885Mar 08 04:40 PM
Blin EmmanuelSVP, Head of CommercializationMar 06Option Exercise0.0081901,553Mar 08 04:41 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528024,746Mar 08 04:40 PM
Caldarella Joseph CSVP & ControllerMar 04Sale64.6412,962837,91646,322Mar 07 05:41 PM
Caforio GiovanniChief Executive OfficerFeb 17Option Exercise22.8920,125460,66188,778Feb 19 04:32 PM
LEUNG SANDRAEVP, General CounselFeb 17Option Exercise22.7314,560330,949319,699Feb 19 04:32 PM
Caforio GiovanniChief Executive OfficerFeb 17Sale63.5812,040765,52776,738Feb 19 04:32 PM
LEUNG SANDRAEVP, General CounselFeb 17Sale63.5710,152645,342309,547Feb 19 04:32 PM
ANDREOTTI LAMBERTODirectorFeb 04Option Exercise0.00148,1800445,820Feb 08 04:31 PM
Paliwal Dinesh CDirectorFeb 01Option Exercise0.003,25703,257Feb 03 06:28 PM
ANDREOTTI LAMBERTODirectorJan 05Sale68.1911,600791,028310,424Jan 06 04:40 PM
ANDREOTTI LAMBERTODirectorJan 04Sale66.9311,600776,332322,024Jan 06 04:40 PM
Elicker John ESVP Pub Affairs & Inv RelationJan 03Option Exercise0.00950053,012Jan 05 06:21 PM
ANDREOTTI LAMBERTODirectorDec 15Sale70.0511,600812,580332,852Dec 16 04:39 PM
ANDREOTTI LAMBERTODirectorDec 14Sale68.0011,600788,843344,452Dec 16 04:39 PM
ANDREOTTI LAMBERTODirectorNov 20Sale67.7611,600786,016501,052Nov 23 04:41 PM
ANDREOTTI LAMBERTODirectorNov 19Sale67.0211,600777,470512,652Nov 23 04:41 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,1000163,957Nov 03 03:45 PM
Elicker John ESVP Pub Affairs & Inv RelationNov 01Option Exercise0.00496052,286Nov 03 03:45 PM
ANDREOTTI LAMBERTODirectorOct 06Sale59.7311,600692,904524,252Oct 08 04:08 PM
ANDREOTTI LAMBERTODirectorOct 05Sale61.9911,600719,027535,852Oct 08 04:08 PM